Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

Introduction: A point mutation in the KRAS gene is the most frequent mutation in NSCLC. It is predominantly detected in codon 12 and 13. For patients with resected NSCLC and adjuvant chemotherapy, recent findings indicate a survival advantage for the subgroup with a KRAS mutation in codon 12 vs. 13. In the present study we analysed differences of overall survival in patients with advanced non-squamous NSCLC in dependence of the location of the KRAS-mutation.Methods: From 10/2009 till 12/2011 we diagnosed 497 patients with non-sqamous NSCLC stage IIIB and IV. KRAS mutation analysis was performed via LightCycler Real-time PCR.Results: A mutation analysis could be completed in 299/497 tissue samples (206 adenocarcinoma (AC) and 93 other non squamous carcinoma). In all other cases the amount of material was not sufficient for this addition analysis. In 76/299 cases (25.4%) a KRAS mutation was detected (30 male, 46 female). In 65/76 (85.5%) cases it was located in codon 12 and in 11/76 (14.5%) on codon 13. No significant difference in overall survival could be proofed for patients with mutations in KRAS codon 12 (median OS 278 days, 176-380 95%CI) versus patients with mutations in KRAS codon 13 (median OS 226 days, 27-429 95%CI; p=0.533).Conclusions: In our monocentric study population with advanced NSCLC the frequency of KRAS mutations in codon 12 and 13 is comparable to other studies. We did not find a prognostic relevance of the mutated gene´s location.

Rating:

Share or cite this content

Citations should be made in the following way:
C. Boch, J. Kollmeier, A. Roth, D. Misch, T. Weiß, A. Streubel, T. Mairinger, T. T. Bauer (Berlin, Germany). The prognostic value of KRAS mutation according to the gene's. Eur Respir J 2014; 44: Suppl. 58, 511

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 The value of miR221 and miR222 as a biomarker in non small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Metabolomic analysis of serum samples from patients with lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 The significance of HSP90AA1, HSP90AB1 and HSP90B1 gene polymorphisms in a Turkish population with non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Lung cancer after lymphoma: Disease characteristics, detection methods and clinical outcome Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 EGFR mutation diagnostic program for NSCLC patients in Poland between 2011-2014 Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Symptom-to-treatment intervals in lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014